Canada: Proposed New Regulations For PM(NOC) Proceedings And CSPs

On July 15, 2017 the government published proposed new Regulations to change the procedure under the Patented Medicines (Notice of Compliance) Regulations to fundamentally change the process from a paper-based court application to a full-blown patent infringement/validity trial, complete with documentary and oral discoveries and live testimony at trial. These new Regulations could come into effect as soon as September 21, 2017. This elimination of the summary proceedings is consistent with the US Orange Book regime under Hatch-Waxman.

Like an animal designed by committee, the current PM(NOC) regime is oddly eccentric and unpopular with all parties concerned. The court had only a paper record upon which to decide often complicated technical evidence. The burden of proof was on the Innovator (the first person or patent owner) to prove that the allegations of non-infringement and invalidity made by the Generic (second person) in the Notice of Allegation were not justified. Appeals by Innovators from unsuccessful applications were moot, because the Notice of Compliance (NOA) had already issued. An unsuccessful application was often followed by a patent infringement and validity lawsuit, resulting in the duplication of efforts by the parties and the court.

By agreeing to the Canada-European Union Comprehensive Economic and Trade Agreement ("CETA"), Canada committed to providing full appeal rights under the Regulations that linked the approval of generic medicines to the protection of patent rights. That commitment necessitated replacing the PM(NOC) court application with a single, fast-tracked, patent infringement/validity trial.

The proposed Regulations will put a greater burden on the parties and the court to have the patent infringement/validity trial proceed to trial and a decision within the 24 month time limit. Wisely, the proposed Regulations provide a limited number of procedural rules and otherwise leave most procedural matters to be dealt with by the Court, to evolve procedural solutions as experience develops.

24 Month Timeline retained

The proposed Regulations would continue the current practice of barring the Minister of Health for up to 24 months from issuing a Notice of Compliance. Also maintained is the requirement that the PM(NOC) action be disposed of within 24 months of commencement of the litigation. From a Canadian perspective, this would be a "fast-track" to trial.

The "first person" and/or the patent owner can sue a "second person" for patent infringement on the basis of the second person's regulatory submission or supplement.  The second person can defend the action and commence a counterclaim to invalidate the patent. No longer at issue will be the question as to whether the Minister of Health should be prohibited from issuing a NOC. The burdens of proof under the new regime would be consistent with those of traditional patent litigation.  The proposed regulations would deem a second person to be an "interested person" who could commence invalidity proceedings.

Under the proposed Regulations, any claim in a patent included on the Patent Register could be addressed and PM(NOC) proceedings would no longer be limited to claims for the medicinal ingredient, the formulation, the dosage form or the use of the medicinal ingredient.

Joinder of other causes of action would be limited. All actions alleging infringement of a patent that could not be litigated under the Regulations, cannot be joined.  Joinder would be possible of separate actions brought by a first person and a patent owner in response to the same NOA as could separate actions brought in response to multiple NOAs that address different patents but relate to the same submission. Patents that could have been litigated in respect of the patent listed on the Patent Register and addressed in an NOA will be prohibited from being litigated afterwards unless the first person or patent owner did not have a reasonable basis for bringing an action under the Regulations within the prescribed period.

Pleadings

Under the proposed Regulations, a second person would still have to serve a NOA on a first-person, but greater detail would have to be provided as to invalidity allegations. A second person would have to provide a detailed legal and factual basis for any allegation of invalidity along with electronic copies of any document relied on in support of the allegation. The second person may ask for and be provided with contact information for any inventor and may request laboratory notebooks, research reports or other documents relevant to establishing the existence of a particular property, advantage or use asserted by the second person to form part of the invention as of the filing date of the application for the patent. The provision of contact information of ex-employees may put an Innovator at risk of breaching European privacy laws.

With respect to non-infringement allegations, the second person must serve, along with its NOA, any portions of its submission or supplement that could be relevant for determining whether a listed patent would be infringed. This will permit a first person or patent owner to determine whether they believe a listed patent will be infringed. A first person or patent owner may move for production of further portions of the submission or supplement after commencing a proceeding.

Confidentiality

Because some of the documents are produced before the discovery process begins, the proposed Regulations allow for a party producing such documents to impose reasonable rules for maintaining their confidentiality, as between the parties. With respect to the court's handling of such documents, it can either adopt the rules designed by the parties or create its own conditions, as it considers just.

Case Management

The Regulatory Impact Analysis Statement says that "[e]arly and active case management will help contribute to the timely resolution of proceedings." That is an understatement. Having a pharmaceutical patent case go to trial and be decided within 24 months will require aggressive case management and cooperation between the parties. Parties and their counsel will be required to act diligently in carrying out their obligations under the proposed Regulations and to cooperate reasonably in expediting any infringement action. Failure to do so may result in the shortening or extension of the 24 month period during which the Minister is prohibited from issuing a NOC and may result in cost sanctions.

The Regulations propose case management for all cases brought under them. A case management conference would be convened shortly after a proceeding is commenced to discuss scheduling, compliance with obligations to provide documents and information, confidentiality rules, whether a sample of the generic product is needed for testing, how claim charts can best be used to expedite resolution, the timing and service of expert evidence and the most efficient and effective means of educating the court about scientific or technological matters.

Interlocutory orders could be appealed but only to the Federal Court of Appeal, with leave.

Damages

The proposed Regulations would continue to allow a second person to seek compensation for losses suffered during the period they were kept off the market as a result of an unsuccessful or discontinued proceeding. All plaintiffs would be made jointly and severally liable for losses suffered by the second person starting after the later of either the date of service of the NOA or the date when the NOC would have issued in the absence of the Regulations. Liability would no longer be limited to losses suffered prior to a specified end date.

Transitional Provisions

The proposed Regulations would come into force on the day section 59 of the CETA comes into force (currently set for September 21, 2017) and would apply to any matters other than those that arose or would arise in relation to a NOA that was served before that date.

Input to Government

Interested persons have only until July 31, 2017 to make representations on the proposed Regulations.

Certificate of Supplementary Protection (CSP)

Additional regulations adopt a patent term extension of up to two years under a Certificate of Supplementary Protection (CSP) analogous to the European Supplementary Protection Certificate (SPC) system.

In summary, a CSP extends the term of an eligible pharmaceutical patent by the difference between the date of the filing of the application for the patent and the date of issuance of the authorization for sale (Notice of Compliance), reduced by five years, and capped at two years. Patents relating to human and veterinary drugs are eligible. CSPs can only be granted for medicines for which regulatory approval in Canada has been granted, and within a prescribed time of applying to do so in another jurisdiction if Canada was not the first country in which approval was sought, and there are other timing requirements. There are also provisions designed to preclude CSPs for variations of medicines for which regulatory approval has been previously granted e.g. enantiomers or formulations, and there can be only one CSP for a medicine. Pure process patent claims are not eligible.

CSPs will be administered by the Minister of Health. The Patent Act  had previously been amended to facilitate the framework for CSPs. As with the proposed Regulations, interested parties have until July 31 to provide comment.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Osler, Hoskin & Harcourt LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Osler, Hoskin & Harcourt LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions